Multi-peptide Vaccine With Basilixumab for Breast Cancer

Summary

Eligible patients will receive subcutaneous vaccinations of the hTERT/survivin/CMV multipeptide vaccine and GM-CSF over a 24 month period. All patients will receive basiliximab 20 mg 1 day prior to the start of vaccinations. Prevnar vaccine will be administered at the time of Vaccines 1,3, and 5. Patients who remain clinically stable after the fourth vaccine, may continue to receive vaccinations every 4 weeks for up to 2 years.

Timeline

Start

2012-06

Primary completion

2015-11-20

Completion

2015-11-20

Drugs

Indications